Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers

References

• Assaraf YG. (2006). The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9:227–46
   PubMed Web of Science ®Google Scholar
• Bi YA, Qiu X, Rotter CJ, et al (2013). Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos 34:452–61
   PubMed Web of Science ®Google Scholar
• Birmingham BK, Bujac SR, Elsby R, et al (2015). Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol 71:341–55
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
   PubMed Web of Science ®Google Scholar
• Deng JW, Song IS, Shin HJ, et al (2008). The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424–33
   PubMed Web of Science ®Google Scholar
• Escobar Y, Venturelli CR, Hoyo-Vadillo C. (2005). Pharmacokinetic properties of pravastatin in Mexicans: an open-label study in healthy adult volunteers. Curr Ther Res Clin Exp 66:238–46
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. (1994). Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 93:1326–31
   PubMed Web of Science ®Google Scholar
• Hatanaka T. (2000). Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397–412
   PubMed Web of Science ®Google Scholar
• Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M. (2003). Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther 74:178–85
   PubMed Web of Science ®Google Scholar
• Hedman M, Antikainen M, Holmberg C, et al (2006). Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 61:706–15
   PubMed Web of Science ®Google Scholar
• Hu M, To KK, Mak VW, Tomlinson B. (2011). The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 7:49–62
   PubMed Web of Science ®Google Scholar
• Hua WJ, Hua WX, Fang HJ. (2012). The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther 30:e234–41
   PubMed Web of Science ®Google Scholar
• Ide T, Sasaki T, Maeda K, et al (2009). Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic information on SLCO1B1 and ABCC2 polymorphisms. J Clin Pharmacol 49:1309–17
   PubMed Web of Science ®Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. (2009). Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703–29
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, et al (2009). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197–203
   PubMed Web of Science ®Google Scholar
• Keogh A, Macdonald P, Kaan A, et al (2000). Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 19: 529–37
   PubMed Web of Science ®Google Scholar
• Kietsiriroje N, Leelawattana R. (2015). Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study. BMC Res Notes 8:294
   PubMedGoogle Scholar
• Kerb R. (2006). Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4–33
   PubMed Web of Science ®Google Scholar
• Kunze A, Huwyler J, Camenisch G, Poller B. (2014). Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos 42:1514–21
   PubMed Web of Science ®Google Scholar
• Lee CA, O'Connor MA, Ritchie TK, et al (2015). Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metab Dispos 43:490–509
   PubMed Web of Science ®Google Scholar
• Lee HK, Hu M, Lui SSh, et al (2013). Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 14:1283–94
   PubMed Web of Science ®Google Scholar
• Lou XY, Zhang W, Wang G, et al (2014). The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. Pharmazie 69:775–9
   PubMed Web of Science ®Google Scholar
• Martin NG, Li KW, Murray H, et al (2012). The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. Br J Clin Pharmacol 73:303–6
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Backman JT, Niemi M. (2008). Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47:463–74
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, et al (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429–40
   PubMedGoogle Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. (2006). SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80:356–66
   PubMed Web of Science ®Google Scholar
• Ogawa K, Hasegawa S, Udaka Y, et al (2003). Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects. J Clin Pharmacol 43:1268–73
   PubMed Web of Science ®Google Scholar
• Pan W, Song IS, Shin HJ, et al (2011). Genetic polymorphisms in Na+-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica 41:501–10
   PubMed Web of Science ®Google Scholar
• Pan HY, Waclawski AP, Funke PT, Whigan D. (1993). Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 27:1029–33
   PubMed Web of Science ®Google Scholar
• Santos PC, Soares RA, Nascimento RM, et al (2011). SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 12:136
   PubMed Web of Science ®Google Scholar
• Schachter M. (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117–25
   PubMed Web of Science ®Google Scholar
• Sigurbjörnsson S, Kjartansdóttir T, Jóhannsson M, et al (1998). A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers. Eur J Drug Metab Pharmacokinet 23:13–18
   PubMed Web of Science ®Google Scholar
• Sponseller CA, Morgan RE, Kryzhanovski VA, et al (2014). Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther 36:1211–22
   PubMed Web of Science ®Google Scholar
• van de Pas NC, Rullmann JA, Woutersen RA, et al (2014). Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations. J Pharmacokinet Pharmacodyn 41:351–62
   PubMed Web of Science ®Google Scholar
• Voora D, Shah SH, Spasojevic I, et al (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54:1609–16
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang G, Li T, et al (2015). Marked alteration of rosuvastatin pharmacokinetics in healthy Chinese with ABCG2 34G> A and 421C> A homozygote or compound heterozygote. J Pharmacol Exp Ther 354:310–15
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al (2009). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–62
   PubMed Web of Science ®Google Scholar
• Yan H, Zhong G, Xu G, et al (2012). Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e00049
   PubMed Web of Science ®Google Scholar